KoolTemp GTS Instant avoids use--and cost--of refrigerants
For several years, NanoCool (Albuquerque, NM) has been offering an innovative chilling technology for cold chain shipments, based on evaporative cooling rather than refrigerant packs or dry ice. Now, it is bringing the global reach of Cold Chain Technologies (CCT; Holliston, MA) to its side with a partnership that gives it access to CCT’s business partners in Europe and elsewhere. CCT is now offering the KoolTemp GTS Instant container, first unveiled at the Cool Chain Logistics Conference (Jan 25-27, Frankfurt).
The NanoCool technique uses a bladder of very low-pressure water as part of the container. When the bladder is punctured, the water begins evaporating, and the heat consumed in that phase change generates “on demand” cooling. The rest of the package uses fairly standard packaging and insulation materials (according to NanoCool literature, there are some instances where the evaporative cooling is complemented with dry ice or other refrigerant). The end result is upwards of 96 hours of maintaining 2-8°C conditions, in boxes with capacities up to about 54 liters.
By reducing or avoiding refrigerants altogether, notes Jamie Chasteen, senior product manager, the GTS Instant package saves weight and materials, and doesn’t require pre-conditioning of the package. In theory, too, the cooling could be initiated at various points in the supply chain (for example, after leaving a temperature-controlled storage area).
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
An Exploration of Compounding Practices
May 22nd 2025In a Q&A with Pharma Commerce, Kurt Lunkwitz, ProRx Pharma’s COO, uncovers the stringent requirements that 503B outsourcing facilities must abide by under the Drug Quality and Security Act, while also shedding light on the FDA’s impact when it comes to improving the safety, quality, and trust in compounded drugs.
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
485 Route 1 South,
Building F, Suite 210
Iselin, NJ 08830